Literature DB >> 14654658

The Maternal Phenylketonuria International Study: 1984-2002.

Richard Koch1, William Hanley, Harvey Levy, Kim Matalon, Reuben Matalon, Bobbye Rouse, Frederick Trefz, Flemming Güttler, Colleen Azen, Larry Platt, Susan Waisbren, Keith Widaman, Jiaping Ning, Eva G Friedman, Felix de la Cruz.   

Abstract

OBJECTIVE: The purpose of this report is to review the obstetric medical, psychological, and nutritional aspects and outcome of the women and offspring enrolled in the Maternal Phenylketonuria Study, which was established to assess the efficacy of a phenylalanine (Phe)-restricted diet in preventing the morbidity associated with this disorder.
METHODS: A total of 382 women with hyperphenylalaninemia (HPA) were enrolled in the study and completed 572 pregnancies. Outcome measures were analyzed with chi2, Fisher exact text, analysis of variance, t test, Wilcoxon nonparametric test, and multiple logistic regression. Outcome measures were stratified according to maternal HPA classification and the time when dietary control was achieved.
RESULTS: Optimal birth outcomes occurred when maternal blood Phe levels between 120 and 360 micromol/L were achieved by 8 to 10 weeks of gestation and maintained throughout pregnancy (trimester averages of 600 micromol/L). Mothers with mild HPA achieved similar birth outcomes as mothers who were in control preconceptually and those in control by 8 to 10 weeks of pregnancy.
CONCLUSIONS: Before conception, counseling and early entrance into a prenatal care program is essential in achieving optimal fetal outcome in women with HPA. The achievement of pre- and periconceptional dietary control with a Phe-restricted diet significantly decreased morbidity in the offspring of women with HPA.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14654658

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  35 in total

1.  Maternal phenylketonuria: low phenylalaninemia might increase the risk of intra uterine growth retardation.

Authors:  Raphaël Teissier; Emmanuel Nowak; Murielle Assoun; Karine Mention; Aline Cano; Alain Fouilhoux; François Feillet; Hélène Ogier; Emmanuel Oger; Loïc de Parscau
Journal:  J Inherit Metab Dis       Date:  2012-06-05       Impact factor: 4.982

2.  Neurobehavioral problems associated with phenylketonuria.

Authors:  Steven D Targum; William Lang
Journal:  Psychiatry (Edgmont)       Date:  2010-12

3.  Maternal phenylketonuria: report from the United Kingdom Registry 1978-97.

Authors:  P J Lee; D Ridout; J H Walter; F Cockburn
Journal:  Arch Dis Child       Date:  2005-02       Impact factor: 3.791

4.  Use of sapropterin dihydrochloride in maternal phenylketonuria. A European experience of eight cases.

Authors:  François Feillet; Ania C Muntau; François-Guillaume Debray; Amelie S Lotz-Havla; Alexandra Puchwein-Schwepcke; Ma'atem Béatrice Fofou-Caillierez; Francjan van Spronsen; Fritz Friedrich Trefz
Journal:  J Inherit Metab Dis       Date:  2014-05-01       Impact factor: 4.982

5.  Pregnancy issues in inherited metabolic disorders.

Authors:  Philip J Lee
Journal:  J Inherit Metab Dis       Date:  2006 Apr-Jun       Impact factor: 4.982

6.  Maternal phenylketonuria in Turkey: outcomes of 71 pregnancies and issues in management.

Authors:  Yılmaz Yıldız; Hatice Serap Sivri
Journal:  Eur J Pediatr       Date:  2019-05-03       Impact factor: 3.183

Review 7.  Preconception healthcare and congenital disorders: systematic review of the effectiveness of preconception care programs in the prevention of congenital disorders.

Authors:  Geordan D Shannon; Corinna Alberg; Luis Nacul; Nora Pashayan
Journal:  Matern Child Health J       Date:  2014-08

8.  Maternal phenylketonuria: the French survey.

Authors:  François Feillet; Véronique Abadie; Jacques Berthelot; Nicole Maurin; Hélène Ogier; Michel Vidailhet; Jean-Pierre Farriaux; Loic de Parscau
Journal:  Eur J Pediatr       Date:  2004-07-06       Impact factor: 3.183

9.  The clinical content of preconception care: genetics and genomics.

Authors:  Benjamin D Solomon; Brian W Jack; W Gregory Feero
Journal:  Am J Obstet Gynecol       Date:  2008-12       Impact factor: 8.661

Review 10.  Sapropterin: a review of its use in the treatment of primary hyperphenylalaninaemia.

Authors:  Mark Sanford; Gillian M Keating
Journal:  Drugs       Date:  2009       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.